Foundation Medicine and Agios Pharmaceuticals entered a multiyear diagnostic partnership for Agios’ lead programs in cancer metabolism. The programs focus on developing new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes. The companies are collaborating to identify tumor genomic alterations that can be used to identify which patients are most likely to respond to Agios’ IDH1 and IDH2 drug candidates, and to develop and potentially commercialize diagnostic products for these programs.
“Foundation Medicine’s comprehensive cancer genomic profile helps match a patient’s individual molecular alterations with relevant targeted therapies,” said Michael J. Pellini, M.D., CEO of Foundation Medicine. “For this reason, it is important for us to partner with innovative biopharmaceutical companies like Agios to help expand the number of targeted therapies available and open new treatment options for patients.”
Agios is focused on discovering and developing drugs in the fields of cancer metabolism and rare metabolic genetic diseases.
Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers, and drug developers. According to the company, its initial clinical assay, FoundationOneTM, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials.